The project described was supported by the DHHS grant R43CA177067(Uckun FM)from the National Cancer Institute.The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health.Uckun FM was also supported in part by DHHS grants P30CA014089,U01-CA-151837,R01CA-154471 and R21-CA-164098(Uckun FM)from the National Cancer Institute;by the V-Foundation,Nautica Triathlon as well as the Ronald McDonald House Charities of Southern California.
Aim:CD22ΔE12 as an oncogenic driver lesion in aggressive and drug-resistant B-precursor acute lymphoblastic leukemia(BPL)cells.The purpose of the present study was to identify the CD22ΔE12-specific signature transcr...